マルタ - 英語 - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - pravastatin sodium - tablet - pravastatin sodium 20 mg - lipid modifying agents

マルタ - 英語 - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - pravastatin sodium - tablet - pravastatin sodium 40 mg - lipid modifying agents

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 80 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium oxide; povidone; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; iron oxide yellow - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. lipostat is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. lipostat is indicated in patients with unstable angina pectoris (see clinical trials). lipostat is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium oxide; povidone; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; iron oxide yellow - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. lipostat is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. lipostat is indicated in patients with unstable angina pectoris (see clinical trials). lipostat is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium oxide; povidone; microcrystalline cellulose; iron oxide yellow; croscarmellose sodium; magnesium stearate - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. lipostat is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. lipostat is indicated in patients with unstable angina pectoris (see clinical trials). lipostat is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium oxide; povidone; microcrystalline cellulose; iron oxide yellow; croscarmellose sodium; magnesium stearate - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. lipostat is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. lipostat is indicated in patients with unstable angina pectoris (see clinical trials). lipostat is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 80 mg - tablet, uncoated - excipient ingredients: povidone; croscarmellose sodium; iron oxide yellow; microcrystalline cellulose; magnesium stearate; lactose monohydrate; magnesium oxide - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose; sodium stearylfumarate; iron oxide yellow - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. cholvastin is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. cholvastin is indicated in patients with unstable angina pectoris see clinical trials). 4. cholvastin is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials). 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. vastoran is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. vastoran is indicated in patients with unstable angina pectoris see clinical trials). 4. vastoran is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose; sodium stearylfumarate; iron oxide yellow - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. cholvastin is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. cholvastin is indicated in patients with unstable angina pectoris see clinical trials). 4. cholvastin is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials). 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. vastoran is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. vastoran is indicated in patients with unstable angina pectoris see clinical trials). 4. vastoran is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials).

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets are indicated to: - reduce the risk of myocardial infarction (mi). - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. pravastatin sodium tablets are indicated: - as an adjunct to diet to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apob), and triglyceride (tg) levels and to increase high-density lipoprotein cholesterol